YOLFTbeta
Cansino Biologics Inc

Cansino Biologics Inc

688185 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

68.13CNY-5.63 (-7.63%)

Price History

Full chart

Market Stats

Previous Close73.76
Open73.30
Day Range67.77 – 73.49
52-Week Range46.89 – 102.64
Volume6.84M
Market Cap25.36B
P/E (TTM)641.50
Forward P/E0.00
EPS0.16
Dividend Yield0.00%
Beta1.24
50-Day Avg65.49
200-Day Avg63.49

About

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; and CS-2023 to treat meningitis. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Xuefeng Yu Ph.D.
  • Employees1.18K
  • Headquarters401-420, Biomedical Park, Tianjin, China, 300457, China
  • Websitehttps://cansinotech.com

Leadership

  • Dr. Xuefeng Yu Ph.D.Co-Founder, Executive Chairman, CEO & GM · b. 1964
  • Dr. Shou-Bai Chao Ph.D.COO, Deputy GM & Executive Director · b. 1963
  • Ms. Jing WangChief Commercial Officer, Deputy GM & Executive Director · b. 1981
  • Dr. Tao Zhu Ph.D.Co-Founder, Deputy GM & Chief Scientific Officer · b. 1973
  • Dr. Dongxu Qiu MBA, Ph.D.Co-Founder, Executive VP & Deputy GM · b. 1960
  • Ming LiuActing Head of Finance
  • Bei Bei GaoAccounting Supervisor
  • Mr. Chunlin XinSenior Director of New Technology Department
  • Mr. Yonghui WuVice President of Marketing
  • Mr. Jin CuiBoard Secretary · b. 1987

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue8.20M9.18M8.66M15.61M24.89M4.30B1.03B357.08M846.34M1.07B
Growth (%)-+12.04%-5.73%+80.36%+59.43%+17174.82%-75.94%-65.49%+137.01%+26.18%
Cost of Revenue51.67M68.10M113.65M241.00K14.73M1.30B1.22B800.83M262.76M260.13M
Gross Profit8.20M9.18M8.66M15.37M10.16M3.00B-183.71M-443.75M583.58M1.07B
Gross Margin100.00%100.00%100.00%98.46%40.82%69.82%-17.76%-124.27%68.95%100.00%
Operating Expense60.88M72.98M147.23M215.62M407.98M1.06B997.00M1.49B958.80M1.04B
Operating Income-52.69M-63.80M-138.58M-200.25M-397.82M1.94B-1.18B-1.94B-375.22M23.91M
Operating Margin-642.90%-694.79%-1600.95%-1282.64%-1598.30%45.14%-114.12%-542.30%-44.33%2.24%
EBITDA-43.45M-55.94M-126.32M-131.40M-377.73M2.02B-962.04M-1.67B-135.62M207.16M
EBITDA Margin-530.19%-609.19%-1459.35%-841.66%-1517.58%47.03%-92.99%-469.07%-16.02%19.40%
Net Income-49.85M-64.45M-138.28M-156.77M-396.64M1.91B-909.43M-1.48B-378.88M27.87M
Net Income Margin-608.31%-701.92%-1597.52%-1004.14%-1593.56%44.52%-87.90%-415.23%-44.77%2.61%
R&D51.89M68.10M113.65M151.75M428.49M878.72M778.26M637.99M416.12M313.04M
R&D as % of Total Revenue633.19%741.67%1312.92%971.99%1721.51%20.44%75.22%178.67%49.17%29.31%
Interest Expense-30.40K08.98M26.50M20.42M41.83M64.14M60.16M39.61M
Interest Expense % of Total Revenue-0.33%0.00%57.53%106.45%0.47%4.04%17.96%7.11%3.71%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets326.17M866.36M795.88M1.78B6.75B11.87B11.47B9.32B7.96B7.18B
Total Liabilities111.70M259.03M293.56M313.98M677.22M3.33B4.22B4.03B3.05B-4.93B
Total Equity214.47M607.33M502.32M1.47B6.07B8.00B6.75B5.27B4.91B4.93B
Cash52.55M18.25M57.38M202.45M4.45B5.46B3.39B2.05B1.56B1.22B
Total Debt69.33M108.33M150.00M166.80M142.54M1.37B2.70B2.70B2.01B-
Net Debt16.78M90.09M92.62M-35.65M-4.30B-4.08B-694.19M653.34M456.91M55.79M

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-34.38M-56.30M-123.64M-170.19M-469.39M2.01B-1.89B-916.25M-168.79M77.86M
Investing Cash Flow-173.54M-461.49M117.63M-797.77M-182.71M-2.53B-1.19B-441.62M3.96M-
Financing Cash Flow150.81M484.37M45.05M1.09B4.94B1.56B854.60M-7.58M-334.18M-
Capital Expenditure126.08M185.89M160.67M116.95M270.77M1.20B1.08B610.47M457.64M243.90M
Free Cash Flow-160.46M-242.19M-284.31M-287.14M-740.16M811.42M-2.96B-1.53B-626.42M-166.04M
Dividends Paid336.31K4.63M7.59M8.78M6.69M14.10M193.93M3.63M63.78M-
FCF to OCF466.69%430.18%229.96%168.72%157.69%40.28%156.95%166.63%371.13%-213.27%
Dividend Paid to FCF-0.21%-1.91%-2.67%-3.06%-0.90%1.74%-6.55%-0.24%-10.18%-

Earnings

Report DateOct 27, 2020Mar 26, 2021Apr 30, 2021Aug 27, 2021Oct 29, 2021Feb 25, 2022Apr 28, 2022Aug 26, 2022Oct 28, 2022Feb 27, 2023Apr 28, 2023
EPS Estimate-----------
EPS Actual-0.32-0.89-0.063.841.602.350.49-0.44-1.97-1.76-0.57
Surprise-----------
TimingPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hours

Key Statistics & Ratios

Market Cap25.36B
Enterprise Value12.49B
Trailing P/E641.50
Forward P/E0.00
Price / Sales20.52
Price / Book4.23
EPS0.16
Book Value20.15
Revenue (TTM)1.24B
Gross Profit (TTM)916.35M
EBITDA86.62M
Profit Margin3.29%
Operating Margin0.91%
Return on Equity0.82%
Return on Assets-0.80%
Shares Outstanding114.37M
Shares Float159.89M
Beta1.24
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20221×
0.80Aug 23, 2022